{"id":"albutrepenonacog-alfa-1-unt-idelvion","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Thrombotic events (rare)"},{"rate":null,"effect":"Inhibitor development (alloimmunization)"}]},"_chembl":{"chemblId":"CHEMBL5315076","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This drug is a genetically engineered Factor IX variant fused to albumin, which extends its half-life and improves pharmacokinetics compared to standard Factor IX concentrates. It restores the intrinsic coagulation pathway by providing the missing clotting factor, enabling normal thrombin generation and fibrin clot formation in patients with hemophilia B (Factor IX deficiency).","oneSentence":"Albutrepenonacog alfa is a recombinant fusion protein that replaces deficient Factor IX (Christmas factor) to restore blood coagulation in hemophilia B patients.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:26:55.609Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemophilia B (Factor IX deficiency) — routine prophylaxis and on-demand treatment of bleeding episodes"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Albutrepenonacog Alfa 1 UNT [IDELVION]","genericName":"Albutrepenonacog Alfa 1 UNT [IDELVION]","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Albutrepenonacog alfa is a recombinant fusion protein that replaces deficient Factor IX (Christmas factor) to restore blood coagulation in hemophilia B patients. Used for Hemophilia B (Factor IX deficiency) — routine prophylaxis and on-demand treatment of bleeding episodes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}